MA-PRECISELY
1.12.2022 12:01:41 CET | Business Wire | Press release
Precisely, the global leader in data integrity, today announced it is working with Amazon Web Services (AWS) on its AWS Mainframe Modernization service. The integration offers real-time replication of mainframe data to AWS leveraging Precisely Connect, allowing customers to securely and efficiently migrate data, as well as access mainframe data on AWS for more powerful analytics.
This new scope of work delivers a mainframe modernization solution to the market that allows customers to replicate mainframe data onto AWS with zero downtime. The functionality allows customers to build resilient, high-performance data pipelines that connect data from their mainframe databases to AWS services like Amazon Relational Database Service (Amazon RDS), Amazon Aurora, Amazon Simple Storage Service (Amazon S3), Amazon EMR, Amazon Managed Streaming for Apache Kafka (MSK), Amazon Redshift, Snowflake on AWS, and more. By accelerating access to mainframe data on AWS, businesses can get mainframe migration projects done on time and on budget, all while extending the value of mission-critical, and high investment, mainframe systems. The integration solution works within a business’s existing architecture, allowing teams to future-proof solutions and be flexible when introducing new applications and use cases.
Customers that have already begun taking advantage of these joint capabilities include AAA Life Insurance:
“Our customers rely on us to provide financial protection for their loved ones, and with over 1,500,000 active policies, central to success is real-time access to trusted data across multiple sources. This includes mainframe systems - which are notoriously challenging to integrate effectively,” said Steven Hinzmann, Manager of Application Development at AAA Life Insurance. “Precisely Connect allows us to quickly and easily access vast volumes of historical business and customer data, which is then replicated to the AWS environment where it can be leveraged for advanced analytics. The combination of Precisely’s rich heritage in handling mainframe data with AWS’s cloud platform has been unbeatable for allowing us to innovate and drive the best possible customer experience."
“Data is the lifeblood of the digital economy and the pipelines that carry it are essential to a business’s IT infrastructure,” said Eric Yau, Chief Operating Officer at Precisely. “Together with AWS, we can help our customers to maximize their data and investments - unlocking the true potential of their critical data assets to power their business by making critical data assets available for AWS and for advanced analytics.”
“AWS and Precisely empower our customers to build trust in their data,” said Bill Platt, General Manager for Migration Services at AWS. “By integrating data from complex mainframe systems directly onto AWS, customers can rely on their data to be the driving force of confident analytics, and ensure they are deriving maximum value from their infrastructure investments.”
Learn more about the work between Precisely and AWS here, or visit Precisely at AWS re:Invent to speak with its team of data integrity experts.
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005545/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom